Skip to main content
. 2022 Oct 19;2022:6100176. doi: 10.1155/2022/6100176

Figure 1.

Figure 1

(a) Heat map to identify differentially expressed lncRNAs between cisplatin-resistant and cisplatin-sensitive patients. (b) LINC02389 expression in non-small-cell lung cancer patients and adjacent normal tissues. (c) LINC02389 expression in recurrent and nonrecurrent non-small-cell lung cancer patients. (d) Survival analysis for LINC02389 high and low expressed non-small-cell lung cancer patients. (e, f) MDA and GSH expressions in recurrent and nonrecurrent non-small-cell lung cancer patients. (g, h) MDA and GSH expressions in LINC02389 high and low expressed non-small-cell lung cancer patients.